Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Al Jazeera on MSN2h
Could weight loss drugs fix UK’s unemployment problem?
The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...
Lilly Sues US Agency Over Blocking of Drug-Rebate Program
Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...
Oil heads for weekly loss as Chinese demand continues to underperform
Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...
Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Fox 139h
New FDA rules target those ubiquitous TV drug commercials
The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
verywellhealth13h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
MSCS joins "mass action" suit against drug companies over insulin costs
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.